In the latest session, Puma Biotechnology Inc (NASDAQ: PBYI) closed at $5.60 up 0.18% from its previous closing price of $5.59. In other words, the price has increased by $+0.01 from its previous closing price. On the day, 528484 shares were traded.
Ratios:
For a deeper understanding of Puma Biotechnology Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.81 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.05. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.57. In the meantime, Its Debt-to-Equity ratio is 2.09 whereas as Long-Term Debt/Eq ratio is at 1.36.
Goldman Downgraded its Neutral to Sell on October 08, 2019, whereas the target price for the stock was revised from $24 to $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 03 ’24 when AUERBACH ALAN H sold 41,396 shares for $4.49 per share. The transaction valued at 185,698 led to the insider holds 6,936,947 shares of the business.
NOUGUES MAXIMO F sold 15,682 shares of PBYI for $70,348 on Jan 03 ’24. The Chief Financial Officer now owns 128,666 shares after completing the transaction at $4.49 per share. On Jan 03 ’24, another insider, Ludwig Jeffrey Jerome, who serves as the Chief Commercial Officer of the company, sold 12,956 shares for $4.49 each. As a result, the insider received 58,119 and left with 99,970 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PBYI now has a Market Capitalization of 269.96M and an Enterprise Value of 285.51M. As of this moment, Puma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.41, and their Forward P/E ratio for the next fiscal year is 32.94. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.15 while its Price-to-Book (P/B) ratio in mrq is 4.99. Its current Enterprise Value per Revenue stands at 1.21 whereas that against EBITDA is 6.01.
Stock Price History:
The Beta on a monthly basis for PBYI is 1.28, which has changed by 119.61% over the last 52 weeks, in comparison to a change of 29.19% over the same period for the S&P500. Over the past 52 weeks, PBYI has reached a high of $7.73, while it has fallen to a 52-week low of $2.13. The 50-Day Moving Average of the stock is 5.52, while the 200-Day Moving Average is calculated to be 3.97.
Shares Statistics:
For the past three months, PBYI has traded an average of 618.12K shares per day and 751.63k over the past ten days. A total of 47.65M shares are outstanding, with a floating share count of 37.17M. Insiders hold about 22.90% of the company’s shares, while institutions hold 55.26% stake in the company. Shares short for PBYI as of Feb 29, 2024 were 4.09M with a Short Ratio of 6.62, compared to 3.21M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.49% and a Short% of Float of 9.95%.
Earnings Estimates
There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.22 for the current quarter, with a high estimate of -$0.21 and a low estimate of -$0.23, while EPS last year was $0.03. The consensus estimate for the next quarter is $0.03, with high estimates of $0.11 and low estimates of -$0.07.
Analysts are recommending an EPS of between $0.3 and $0.23 for the fiscal current year, implying an average EPS of $0.26. EPS for the following year is $0.17, with 3 analysts recommending between $0.48 and -$0.07.
Revenue Estimates
A total of 2 analysts believe the company’s revenue will be $41.05M this quarter.It ranges from a high estimate of $41.6M to a low estimate of $40.5M. As of the current estimate, Puma Biotechnology Inc’s year-ago sales were $52.77M, an estimated decrease of -22.20% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $57.3M, an increase of 4.90% over than the figure of -$22.20% in the same quarter last year. There is a high estimate of $58M for the next quarter, whereas the lowest estimate is $56.6M.
A total of 3 analysts have provided revenue estimates for PBYI’s current fiscal year. The highest revenue estimate was $221.5M, while the lowest revenue estimate was $216M, resulting in an average revenue estimate of $219.23M. In the same quarter a year ago, actual revenue was $235.6M, down -6.90% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $217.03M in the next fiscal year. The high estimate is $235.1M and the low estimate is $186M. The average revenue growth estimate for next year is down -1.00% from the average revenue estimate for this year.
